Mirjam de With

432 total citations
13 papers, 186 citations indexed

About

Mirjam de With is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mirjam de With has authored 13 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mirjam de With's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer therapeutics and mechanisms (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Mirjam de With is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer therapeutics and mechanisms (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Mirjam de With collaborates with scholars based in Netherlands, Italy and Belgium. Mirjam de With's co-authors include Ron H.J. Mathijssen, Ron H. N. van Schaik, Sander Bins, Maja Matić, Ruben A.G. van Eerden, Romano Danesi, Marzia Del Re, Dennis A. Hesselink, Laure Elens and Esther Oomen‐de Hoop and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Mirjam de With

13 papers receiving 184 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mirjam de With Netherlands 8 88 71 53 30 24 13 186
C. Tyler Kirkland United States 4 108 1.2× 85 1.2× 44 0.8× 53 1.8× 22 0.9× 6 292
Yusuke Hara Japan 11 78 0.9× 193 2.7× 58 1.1× 28 0.9× 29 1.2× 30 383
Jan B. Ruit Netherlands 5 145 1.6× 67 0.9× 20 0.4× 39 1.3× 23 1.0× 6 204
Kiyoshi Nishiyama Japan 10 82 0.9× 76 1.1× 33 0.6× 23 0.8× 9 0.4× 20 374
Akihisa Kaneko Japan 11 63 0.7× 44 0.6× 38 0.7× 21 0.7× 6 0.3× 24 261
Chitra Saran United States 7 107 1.2× 59 0.8× 29 0.5× 28 0.9× 6 0.3× 10 200
Marie‐Luise Buchholtz Germany 6 24 0.3× 108 1.5× 44 0.8× 38 1.3× 15 0.6× 7 284
Amy Sion United States 5 115 1.3× 33 0.5× 44 0.8× 98 3.3× 38 1.6× 8 238
Carin A.T.C. Lunenburg Netherlands 9 226 2.6× 130 1.8× 109 2.1× 38 1.3× 30 1.3× 12 358
Caroline Klindt Germany 7 222 2.5× 111 1.6× 15 0.3× 34 1.1× 30 1.3× 12 417

Countries citing papers authored by Mirjam de With

Since Specialization
Citations

This map shows the geographic impact of Mirjam de With's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirjam de With with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirjam de With more than expected).

Fields of papers citing papers by Mirjam de With

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirjam de With. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirjam de With. The network helps show where Mirjam de With may publish in the future.

Co-authorship network of co-authors of Mirjam de With

This figure shows the co-authorship network connecting the top 25 collaborators of Mirjam de With. A scholar is included among the top collaborators of Mirjam de With based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirjam de With. Mirjam de With is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
With, Mirjam de, Leni van Doorn, Maja Matić, et al.. (2023). Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical Pharmacokinetics. 62(11). 1589–1597. 7 indexed citations
2.
With, Mirjam de, Leni van Doorn, Esther Oomen‐de Hoop, et al.. (2023). Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. Biomedicine & Pharmacotherapy. 159. 114232–114232. 13 indexed citations
3.
With, Mirjam de, Erika Cecchin, Vincent Haufroid, et al.. (2023). Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open. 8(2). 101197–101197. 38 indexed citations
4.
With, Mirjam de, Gemma Brufau, Femke M. de Man, et al.. (2022). DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events. JCO Precision Oncology. 6(6). e2200180–e2200180. 4 indexed citations
5.
Veerman, G., Mirjam de With, Sander Bins, et al.. (2022). Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer. Drug Resistance Updates. 62. 100832–100832. 12 indexed citations
6.
7.
With, Mirjam de, Daan P. Hurkmans, Esther Oomen‐de Hoop, et al.. (2021). Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers. 13(6). 1370–1370. 9 indexed citations
8.
Eerden, Ruben A.G. van, Mirjam de With, Laure Elens, et al.. (2021). CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?. Frontiers in Genetics. 12. 711943–711943. 45 indexed citations
9.
With, Mirjam de, Femke M. de Man, Geert‐Jan Creemers, et al.. (2021). Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. Journal of Clinical Oncology. 39(15_suppl). 3574–3574. 2 indexed citations
10.
With, Mirjam de, Rajbir Singh, Samira El Bouazzaoui, et al.. (2020). The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 85(3). 547–553. 6 indexed citations
11.
Goey, Andrew K.L., Mirjam de With, Esther Oomen‐de Hoop, et al.. (2019). Effects of Pharmacogenetic Variants on Vemurafenib-related Toxicities in Patients with Melanoma. Pharmacogenomics. 20(18). 1283–1290. 3 indexed citations
12.
Man, Femke M. de, Koen G. A. M. Hussaarts, Mirjam de With, et al.. (2018). Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. Clinical Pharmacology & Therapeutics. 105(6). 1456–1461. 17 indexed citations
13.
Man, Femke M. de, Koen G. A. M. Hussaarts, Mirjam de With, et al.. (2018). Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib. Annals of Oncology. 29. viii158–viii158. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Tyler Kirkland Breakdown of academic impact, for papers by Yusuke Hara Breakdown of academic impact, for papers by Jan B. Ruit Breakdown of academic impact, for papers by Kiyoshi Nishiyama Breakdown of academic impact, for papers by Akihisa Kaneko Breakdown of academic impact, for papers by Chitra Saran Breakdown of academic impact, for papers by Marie‐Luise Buchholtz Breakdown of academic impact, for papers by Amy Sion Breakdown of academic impact, for papers by Carin A.T.C. Lunenburg Breakdown of academic impact, for papers by Caroline Klindt
Rankless by CCL
2026